Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 3.55M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 3.55M.
Avaliação Justa
O PE mais recente da empresa é -2.60, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 4.34M ações, uma redução de 7.88% em relação ao trimestre anterior.
Mantido por James Simons
O Super Investidor James Simons possui 0.00 ações desta empresa.